ICVTS Click here to goto Smart Canula website
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Interact CardioVasc Thorac Surg 2009;9:919-920. doi:10.1510/icvts.2009.215244
© 2009 European Association of Cardio-Thoracic Surgery
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Sinan Simsir
Right arrow Permission Requests
Google Scholar
Right arrow Articles by Fieno, D. S.
Right arrow Articles by Simsir, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fieno, D. S.
Right arrow Articles by Simsir, S.
Related Collections
Right arrow Cardiac - other
Right arrow Mechanical Circulatory Assistance

Case report - Assisted circulation

Left ventricular assist device placement in a patient with end-stage heart failure and human immunodeficiency virus

David S. Fienoa,b, Lawrence S. Czera,b, Ernst R. Schwarza,b and Sinan Simsira,b*

a Cedars-Sinai Medical Center, Division of Cardiology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA, USA
b Cedars-Sinai Medical Center, Division of Cardiothoracic Surgery, Department of Surgery, 8700 Beverly Boulevard, Suite 6215, Los Angeles, CA 91604, USA

*Corresponding author. Tel.: +1-310-423-3851; fax: +1-310-423-0127.

E-mail address: simsirs{at}cshs.org (S. Simsir).

Left ventricular assist device (LVAD) insertion has been used more frequently within the recent years either as a bridge to transplant or as destination therapy in patients with advanced heart failure who fail medical therapy. We present a report of a 60-year-old male patient with end-stage heart failure and cardiomyopathy with a history of human immunodeficiency virus (HIV) infection who underwent LVAD placement as destination therapy. To our knowledge, LVAD placement in this fashion has not been reported previously. Following LVAD implantation, the patient recovered during the course of five weeks and was discharged home from the hospital in good condition. The patient was alive and free of any activity limitations sixteen months postoperatively. We conclude that LVAD placement for end-stage heart failure may be a feasible option as destination therapy in patients with HIV.

Key Words: Left ventricular assist device; Human immunodeficiency virus; Heart failure

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 European Association for Cardio-thoracic Surgery